What is Faron Pharmaceuticals Oy's current stock price?

Faron Pharmaceuticals Oy (FARON.HE) currently trades at EUR 0.4760. Track real-time price changes and historical performance on AllInvestView.

What sector is Faron Pharmaceuticals Oy in?

Faron Pharmaceuticals Oy operates in the Health Care sector. AllInvestView lets you analyze sector allocation across your entire portfolio.

Faron Pharmaceuticals Oy FARON.HE · Stock Open Faron Pharmaceuticals Oy in new tab

0.4760 EUR

Add to portfolio

EPS

-0.22

P/B

-2.94

Beta

1.18

Target Price

1.41 EUR

1M 6M YTD 1Y 2Y 5Y Max

Loading chart...

DCF Valuation

Tweak assumptions to recompute fair value for Faron Pharmaceuticals Oy (FARON.HE)

Currency: EUR

DCF Assumptions

Revenue growth (YoY) 0.10 Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).

EBITDA margin 0.30 Decimal (e.g., 0.30 = 30%).

Capex (% Revenue) 0.04 Decimal (e.g., 0.04 = 4%).

Tax rate 0.20 Decimal (e.g., 0.20 = 20%).

Terminal growth (g, %) 3% Percent number (e.g., 3 = 3%).

Cost of Equity (%) 10% Percent number (e.g., 10 = 10%).

Cost of Debt (%) 5% Percent number (e.g., 5 = 5%).

DCF Result

Fair Value (DCF)

—

Current Price

—

Upside

—

WACC

—

Terminal PV

—

Σ PV of FCFs

—

Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

Faron Pharmaceuticals Oy Analysis (FARON.HE)

Finland Health Care Official Website Stock

Is Faron Pharmaceuticals Oy a good investment? Faron Pharmaceuticals Oy (FARON.HE) is currently trading at 0.4760 EUR. Market analysts have a consensus price target of 1.41 EUR. This suggests a potential upside from current levels.

Investor FAQ

Does Faron Pharmaceuticals Oy pay a dividend?

No, it does not currently pay a dividend.

What asset class is Faron Pharmaceuticals Oy?

Faron Pharmaceuticals Oy is classified as a Stock.

Company Profile

Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company. The company's lead product candidate is Bexmarilimab, a novel anti-Clever-1 humanized antibody that targets a subpopulation of tumor-associated macrophages and converts the highly immunosuppressive M2-like macrophages to a pro-inflammatory state to promote immune activation. It is also developing bexmarilimab for the treatment of hematological and solid tumor cancers; and in combination with care therapies, azacitidine, and other hypomethylating agents in relapsed/refractory myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia. In addition, the company develops receptors involved in regulation of immune response in organ damage and bone marrow regeneration. Faron Pharmaceuticals Oy was founded in 2003 and is headquartered in Turku, Finland.

Trades

No dividend information available for this instrument.

Faron Pharmaceuticals Oy FARON.HE · Stock Open Faron Pharmaceuticals Oy in new tab

Key Metrics

Estimates

DCF Valuation

DCF Assumptions

DCF Result

Explore Premium Features

Faron Pharmaceuticals Oy Analysis (FARON.HE)

Investor FAQ

Company Profile

Fundamentals

Under Construction

Faron Pharmaceuticals Oy FARON.HE · Stock Open Faron Pharmaceuticals Oy in new tab

Key Metrics

Estimates

DCF Valuation

DCF Assumptions

DCF Result

Explore Premium Features

Faron Pharmaceuticals Oy Analysis (FARON.HE)

Investor FAQ

Company Profile

Explore Premium Features

Fundamentals

Under Construction

Community Discussion

Notifications